Human noroviruses (NoVs) cause acute epidemic gastroenteritis. Susceptibility to the majority of NoV infections is determined by genetically controlled secretor-dependent expression of histo-blood group antigens (HBGAs), which are also critical for NoV attachment to host cells. Human NoVs are classified into two major genogroups (genogroup I [GI] and GII), with each genogroup further divided into several genotypes. GII NoVs are more prevalent and exhibit periodic emergence of new variants, suggested to be driven by altered HBGA binding specificities and antigenic drift. Recent epidemiological studies show increased activity among GI NoVs, with some members showing the ability to bind nonsecretor HBGAs. NoVs bind HBGAs through the protruding (P) domain of the major capsid protein VP1. GI NoVs, similar to GII, exhibit significant sequence variations in the P domain; it is unclear how these variations affect HBGA binding specificities. To understand the determinants of possible strainspecific HBGA binding among GI NoVs, we determined the structure of the P domain of a GI.7 clinical isolate and compared it to the previously determined P domain structures of GI.1 and GI.2 strains. Our crystallographic studies revealed significant structural differences, particularly in the loop regions of the GI.7 P domain, altering its surface topography and electrostatic landscape and potentially indicating antigenic variation. The GI.7 strain bound to H-and A-type, Lewis secretor, and Lewis nonsecretor families of HBGAs, allowing us to further elucidate the structural determinants of nonsecretor HBGA binding among GI NoVs and to infer several contrasting and generalizable features of HBGA binding in the GI NoVs.
H
uman noroviruses (NoVs) are the leading cause of nonbacterial acute gastroenteritis worldwide (1) (2) (3) . They belong to the family Caliciviridae and are divided into 6 genogroups (genogroup I [GI] to GVI) (4) . Each genogroup is phylogenetically further divided into several genotypes. GI and GII contain the epidemiologically predominant human NoVs (5-7). Norwalk virus (NV), the prototype human NoV, belongs to GI, genotype 1 (GI.1) (8) . GI NoVs, apart from NV, are not as well studied and understood as their GII counterparts due to their lower prevalence. Recent epidemiological studies, however, show an increase in the prevalence of GI outbreaks worldwide, with different genotypes such as GI.4, GI.6, GI.3, and GI.7 predominating in different geographical regions (9) (10) (11) (12) (13) . A study from Alberta, Canada, showed that GI NoVs were responsible for ϳ37% of all NoV infections from late 2012 to early 2013, with the majority being caused by GI.6 and GI. 7 . This was an ϳ15-fold-higher prevalence than in 2010 (12) . Studies from Brazil have also reported up to ϳ48% of NoV infections as being due to GI NoVs (13, 14) . In the United States, the Centers for Disease Control and Prevention (CDC) also reported increased prevalence of GI viruses, with a 6-fold increase in GI.6 strains compared to the prevalence in 2010 (10) , whereas the GI.7 genotype ranked 4th within all GI outbreaks (15) . In addition, GI NoVs have recently been reported to be a common cause of traveler's diarrhea among U.S. adults traveling to Mexico (16) .
Several studies have shown that susceptibility to human NoVs is determined by genetically controlled expression of histo-blood group antigens (HBGAs), which are also critical for NoV attachment to host cells (17, 18) . HBGAs are oligosaccharides that are classified into different types (types 1 to 4) based on their carbohydrate compositions and the glycosidic linkages of their precur-sor disaccharides (19, 20) . Both the terminal carbohydrate moieties and the internal precursor glycosidic linkage are thought to contribute as recognition sites for NoVs (21, 22) . HBGAs localize to the surface of epithelial cells and in mucosal secretions of secretor-positive individuals. Secretor-positive status is a susceptibility factor for the prototype NV (23, 24) . Nonsecretors were initially thought to be resistant to human NoVs, but recent epidemiological and structural studies with other GI genotypes have challenged this paradigm (11, 13, 25) . The secretor status of an individual is determined by expression of a functional fucosyl transferase 2 (FUT2) enzyme that adds an ␣-fucose (SeFuc) to the ␤-galactose (␤-Gal) of the disaccharide precursor to form the secretor epitope, or H-type HBGA. The H-type HBGA can be further modified by enzyme A or B by adding N-acetylgalactosamine (GalNAc) or Gal to the precursor ␤-Gal to form A-or B-type HBGA, respectively (20) . Similarly, the Lewis (Le) status is determined by the activity of the fucosyl transferase 3 (FUT3) enzyme, which adds an ␣-fucose (LeFuc) to the N-acetylglucosamine (GlcNAc) of the disaccharide precursor to form the Lewis epitope. The sequential addition of carbohydrate moieties by FUT2 and FUT3 along with enzymes A and B gives rise to the secretor and nonsecretor Lewis and ABH families of HBGAs (26) .
The HBGA binding site in the NoVs is located at the distal end of the protruding (P) domain of the major capsid protein VP1. Crystallographic studies of the P domain in complex with HBGAs show that the HBGA binding sites in GI and GII are structurally distinct (27, 28) . In GII NoVs, accumulation of sequence variations and associated structural changes on the surface of the P domain result in altered HBGA binding specificities and antigenic drift. In the GII.4 genotype, this has been associated with the periodic emergence of new variants (18, (29) (30) (31) . GI NoVs also exhibit extensive sequence changes in the vicinity of the HBGA binding site, which could potentially alter HBGA binding specificities and antigenicity and thus contribute to GI NoV evolution. However, unlike the case with GII NoVs, the effect of sequence variations in GI has not been well characterized. Recent studies have shown that in contrast to GI.1, a GI.2 strain has the ability to bind nonsecretor Lewis HBGAs (25) . A longer variable loop region together with a glutamine residue (Q389) is proposed to be critical for such differential HBGA binding, as the Q389N mutation abolished nonsecretor HBGA binding. This raised questions on whether other GI members with distinct sequence variations at these regions can bind nonsecretor HBGAs and, if so, what determinants modulate glycan-binding preferences among GI NoVs and how genotypic differences in GI alter the P domain structure and influence HBGA binding specificities. To answer these questions, we studied a GI.7 NoV clinical isolate, as it showed significant sequence changes in the P domain compared to GI.1 and GI.2, including a Pro (P388) at the position equivalent to Q389 in GI.2, and carried out in vitro binding studies with GI.7 virus-like particles (VLPs) together with systematic crystallographic analysis of the P domain by itself and in complex with various secretor and nonsecretor HBGAs.
Our enzyme-linked immunosorbent assay (ELISA) binding studies clearly showed that GI.7 VLPs bind to nonsecretor HBGAs in addition to secretor HBGAs, despite the Pro residue substitution. Our crystallographic studies showed that sequence variations result in extensive structural differences in the loop regions and that these differences contribute not only to modulating HBGA binding specificities but also possibly to antigenic variations among the GI NoVs. Our studies strongly suggest that it is not the residue composition corresponding to position 389 but the threshold length and structure of the P-loop that are the critical determinants for nonsecretor HBGA binding in GI NoVs.
MATERIALS AND METHODS
Preparation of recombinant VLPs. The cDNA segments ORF2 and ORF3, coding for major and minor capsid proteins VP1 and VP2 of the respective NoV strains, were cloned into the pVL1392 baculovirus transfer vector (Invitrogen). The proteins were overexpressed by infection of Hi-5 cells with recombinant baculovirus, and self-assembled virus-like particles (VLPs) were purified by sequential ultracentrifugation first on a sucrose cushion and then in a CsCl gradient. Following dialysis into phosphate buffer, protein expression and the integrity of resultant VLPs were assessed by Western blotting and electron microscopy. VLPs representative of both GI.1 (GenBank accession number NC_001959) and GI.7 (GenBank accession number JN005886) genotypes were produced. VLPs with the point mutation W375A in the glycan binding site were produced using a previously described recombinant baculovirus construct (28) .
ELISA. All reagents were diluted in 0.1 M sodium phosphate buffer, pH 6.1, with 0.25% fatty acid-free bovine serum albumin (Sigma-Aldrich), and all assay volumes were 100 l. Neutravidin-coated, preblocked, 96-well plates (Pierce Thermo Fisher Scientific) were coated with the following synthetic biotinylated multivalent glycans for 2 h at 25°C: H type 1-polyacrylamide (PAA)-biotin, A antigen-PAA-biotin, or Le a -PAAbiotin (Glycotech). Negative-control wells were coated with biotin hydrazide reagent (Pierce Thermo Fisher Scientific). VLPs representing GI.1, W375A mutant GI.1, and GI.7 (10 g/ml) were added to the plate and allowed to bind for 2 h at 4°C. The plates were then washed with assay buffer 4 times between each incubation. Bound VLPs were detected using NV-specific polyclonal rabbit serum for 1 h at 4°C, followed by horseradish peroxidase-conjugated goat anti-rabbit antibody (Sigma-Aldrich) for 1 h at 4°C. The color was developed by adding tetramethylbenzidine peroxidase liquid substrate (Pierce Thermo Fisher Scientific). The reaction was stopped after 10 min at 25°C by adding 1 M phosphoric acid. Absorbance at 450 nm was measured using a SpectraMax M5 plate reader (Molecular Devices).
Purification and crystallization of GI.7 P domain. The P domain (amino acids [aa] 226 to 526) construct of a GI.7 strain (TCH-060) was cloned into expression vector pMal-C2E (New England BioLabs) and overexpressed in Escherichia coli, followed by protein purification using chromatography techniques as described previously (30) . The purified P domain was then concentrated to ϳ10 mg/ml and stored in 20 mM TrisHCl buffer (pH 8.0) containing 250 mM NaCl, 1 mM dithiothreitol (DTT), and 5 mM MgCl 2 for crystallization trials. Crystallization conditions were screened with commercially available screens using the nanoliter handling system Mosquito (TTP LabTech) at 20°C by the hangingdrop vapor diffusion method. The crystallization drops were examined using a Rock Imager (Formulatrix). Unliganded protein (ϳ10 mg/ml) crystallized under the condition that had 0.2 M sodium formate, 0.1 M bis-tris propane (pH 6.5), and 20% (wt/vol) polyethylene glycol 3350 (PEG 3350). Crystals measuring 0.1 to 0.2 mm were obtained in 2 to 3 weeks. Crystals of P domain that bound to each of the ligands, H-type 2 trisaccharide, A-type 2 tetrasaccharide, A-type 3 tetrasaccharide, Le y tetrasaccharide, Le x tetrasaccharide, and Le a tetrasaccharide (Dextra Laboratories) were obtained by soaking the unliganded P domain crystals for 30 min in a reconstituted crystallization reservoir solution containing 80 mM ligand and 20% glycerol as a cryoprotectant, followed by flash freezing in liquid nitrogen.
Diffraction, data collection, and structure determination. X-ray diffraction data for the unliganded (native) and liganded P domain crystal data were collected on the 5.0.1 beamline at Advanced Light Source (ALS), Lawrence Berkeley National Laboratory. Diffraction data were processed using either HKL2000 (32) , D*TREK (33) , or IMOSFLM (34) . The space group in each case was confirmed using POINTLESS (35) . An initial elec-tron density map was obtained by molecular replacement (MR) using the previously published GI.1 P domain structure (PDB identifier [ID] 2ZL5) as the phasing model using PHASER (36) as implemented in the CCP4 suite (35) . This was followed by ab initio automated model building and solvent addition using ARP/Warp (37) to reduce model bias. Further model building was carried out using COOT (38) software, followed by iterative cycles of refinement and model building using Refmac (39) or PHENIX (40) . During the refinement, both translation, liberation, and screw (TLS) parameters and noncrystallographic symmetry (NCS) constraints were included. The liganded P domain structures were determined similarly except that the native GI.7 P domain structure was used as the initial phasing model. The oligosaccharide moieties of the HBGAs were generated using the SWEET2 package of the Glycosciences.de server (http://www.glycosciences.de), modeled into the electron density using COOT and validated by computing simulated annealing omit maps using PHENIX. Following each cycle of refinement, the model was corrected based on the F obs -F calc difference maps. Stereochemistry of the structures was confirmed using COOT modules and PROCHECK (41) . The stereochemistry of the oligosaccharides, including the allowed conformational angles, was checked using CARP package in the Glycosciences.de server (http://www.glycosciences.de). Data collection and refinement statistics are provided in Table 1 . Electrostatic potential surface was calculated using the PyMOL (http://www.pymol.org) software package, which was also used for generating the final figures. Superposition of the various structures was carried out using either COOT or PyMoL. Ligand interactions were analyzed using COOT and LIGPLOT (42) with donor-to-acceptor distances of between 2.6 Å and 3.3 Å for hydrogen bonding interactions and carbon-carbon distances of between 3.4 Å and 4.5 Å for hydrophobic interactions.
PDB accession codes. The coordinates and structure factors for the protein structures solved in this study have been deposited in the Protein Data Bank (PDB) under the accession codes 4P12 for the unliganded GI.7 P domain structure and P1V (H-type 2), 4P26 (A-type 2), 4P25 (Le y ), 4P2N (Le x ), and 4P3I (Le a ) for the P domain-ligand complexes.
RESULTS
Sequence variations in VP1 of GI NoVs. The TCH-060 strain of NoV used in our studies was isolated from an 11-year-old boy in 2003 at the Texas Children's Hospital, Houston, TX (43) . Phylogenetic analysis of the VP1 amino acid sequence (GenBank accession number AEQ77282.1) confirmed that it belonged to the GI.7 genotype and showed that it is distant from the structurally characterized GI.1 and GI.2 strains (data not shown). To examine the extent and nature of sequence changes in VP1 among GI NoVs particularly in the vicinity of HBGA binding sites, as determined from the crystallographic analysis of HBGA-bound GI.1 and GI.2 P domain structures, we carried out sequence alignment of representative GI VP1 sequences, including that from our GI.7 strain (Fig. 1 ). This analysis showed that the majority of the significant sequence alterations occur in the regions that correspond to the outermost loop regions of the P domain. These loops are labeled A-, B-, P-, and S-loops, following the same convention as in the previous structural study on a GI.2 P domain (25) . In addition to the changes in these loops, our sequence analysis indicated considerable variation in the region neighboring Q389, which we have labeled as the T-loop. This Q389 residue, which is shown to be critical for nonsecretor HBGA binding in the GI.2 strain, is not conserved in all the GI strains. The GI.1 and GI.7 strains have a Pro residue at this position ( Fig. 1 ), as does a GI.3 strain (JKPG) associated with infection in nonsecretors (11), whereas some others have Asn (Fig. 1) . Further, the P-loop region, whose longer length has been identified as critical for nonsecretor HBGA binding in GI.2, exhibits considerable variation. Compared to GI.2, this region has a 4-residue deletion in GI.1 and a 2-residue deletion in GI.7.
In vitro analysis of HBGA binding in GI.7 NoV. To investigate how these sequence changes in the P domain may influence HBGA binding in GI.7 NoV, we carried out in vitro ELISA binding studies of GI.7 VLPs with various secretor and nonsecretor HBGAs (Fig. 2) . Our results show (Fig. 2 ) that both GI.1 and GI.7 VLPs bound secretor HBGAs, whereas in the W375A mutant VLPs, all HBGA binding interactions were ablated. In contrast to GI.I, the GI.7 VLPs also bind Le a , a nonsecretor HBGA, despite a Pro residue at the position corresponding to Q389 in GI.2. Known HBGA binding profiles of various GI NoVs, including GI.7 (present study), are summarized in Table 2 . To understand how the sequence variations in the GI.7 P domain translate to structural changes that result in the observed HBGA binding, we carried out systematic crystallographic analysis of the unliganded GI.7 P domain, followed by its complex with various HBGAs, including nonsecretor HBGAs.
Unliganded GI.7 P domain structure. The recombinant GI.7 P domain (residues 225 to 526) was cloned and overexpressed in E. coli and purified to homogeneity for crystallization trials. Crystals of the P domain belonging to the P1 space group with four molecules in the asymmetric unit diffracted to ϳ1.6 Å. The structure was determined using molecular replacement techniques and refined to a final R fac /R free of 0.15/0.18 (Table 1) . Structural comparison of the four molecules in the asymmetric unit showed that they are very similar to one another, with an average root mean square deviation (RMSD) of ϳ0.5 Å. These four molecules in the asymmetric unit form two very similar dimers FIG 1 Amino acid sequence alignment of representative GI variants. Only residues from aa 281 to 446 (GI.7 numbering) in the P domain of VP1 are shown, and they represent primarily the P2 subdomain (aa 281 to 410) and a part of the PI subdomain (aa 411 to 446) labeled and shown as a dashed line. The GI.7 strain (GI.7_TCH_2003) used in this study is shown as the first sequence, and the GI.1 (GI.1_NV) and GI.2 (GI.2_FUV258) strains used to compare and contrast in this study are shown as second and third sequences, respectively. Regions of high sequence variability, shown inside the boxes, are named as A-, B-, P-, S-, T-, and U-loops based on previous GI P domain structures. The residues corresponding to Q389 (circled in black) in the GI.2 FUV 258 strain that was shown to be critical for nonsecretor binding is shown with an arrow. The amino acids participating in HBGA interactions in two or more strains are shown with asterisks, and those unique to GI.7 are shown with pound signs. Every residue is shown by a dot above the sequences, every 5th residue is indicated by a dash, and every 10th residue is numbered according to the GI.7 numbering. The GenBank accession numbers for the various sequences represented here are as follows: AEQ77282.1 for GI.7_TCH 2003, NP_056821.2 for GI.1_NV, BAC05516.1 for GI.2_FUV258, ACX33982.1 for GI.3_JKPG, AAA16285.1 for GI.3_DSV, BAB18267.1 for GI.4_Chiba, AFH88383.1 for GI.6_2010, AFC89659.1 for GI.7_2010, ADB54834.1 for GI.8_2008, AAN15140.1 for GI.8_2008 Boxer, and AEY77023.1 for GI.9_2008. (Fig. 3A) . The overall structure of the GI.7 P domain is similar to the P domain structures of other GI NoVs. As in other P domain structures (25, 27, 44) , the GI.7 P domain consists of a well-defined P2 subdomain (residues 280 to 412) composed of a sixstranded antiparallel ␤-barrel with elaborate loops connecting the ␤-strands that is inserted between the N and C termini of the P1 subdomain (residues 225 to 279 and 413 to 526) consisting of a twisted antiparallel ␤-sheet and an ␣-helix (Fig. 3B) .
Structural comparison between the GI P domain structures. To examine whether the sequence alterations in the GI.7 P domain translate into structural changes, we superimposed one of the subunits from the GI.7 P dimer with the corresponding subunit of the P dimer of GI.1 (Fig. 3C ) and GI.2 strains (data not shown). These structures superimposed with an average RMSD of ϳ1.5 Å. Although the overall P domain structure is conserved, significant structural differences (Ͼ2 Å) are observed in the outermost loop regions in the P2 subdomain that include the A-loop (aa 368 to 378), B-loop (aa 295 to 303), P-loop (aa 338 to 350), and T-loop (aa 387 to 395) (indicated in magenta in Fig. 3B and C) . In addition, noticeable changes are also observed in the S-loop (aa 432 to 442), which is in the P1 subdomain, and in another loop (aa 403 to 412) at the junction of the P1 and P2 subdomains that is named the U-loop.
The most prominent difference is observed in the A-and Bloops. The distal end of the A-loop in the GI.7 P domain deviates by an average of ϳ8 Å from the A-loop in the GI.1 and GI.2 P domains and by about ϳ7.5 Å from the B-loop (Fig. 3D ). This structural comparison also revealed that these two loops, which lie in close proximity with each other at the top of the P2 subdomain, can exist in at least two conformations: a closed conformation as observed in the GI.1 and GI.2 P domain structures and a novel open conformation as observed in the GI.7 P domain structure (Fig. 3D ). While these two loops are separated by ϳ6 Å in the GI.1 and GI.2 structures, they are separated by as much as ϳ17.5 Å in the GI.7 P domain structure. Such a large distance between these two loops in the GI.7 P domain exposes a considerably larger surface area underneath that can potentially contribute to differential antigenic presentations. The open conformation in the GI.7 P domain is the result of sequence variations in these loops that lead to longer antiparallel ␤-sheets than in the GI.1 and GI.2 strains.
The P-and S-loops also show considerable differences. In the context of the dimer, the P-and S-loops from the opposing subunits lie in close proximity (Fig. 3E) . In the GI.2 P domain dimer, these two loops, which are longer than in the GI.1 P domain dimer, are involved in the formation of the nonsecretor HBGA binding site. In the GI.7 P domain dimer, these two loops are of intermediate length; while the P-loop lies at an intermediate position compared to GI.1 and GI.2 dimers, the S-loop deviates by ϳ8 Å. Structural alterations in the T-loop (Fig. 3F) are unique to GI.7. The T-loop is shorter in the GI.7 P domain and deviates by ϳ4.5 Å compared to the case with GI.1 and GI.2 strains, bringing this loop closer to the HBGA binding site.
These sequence and structural variations between these GI strains also translate to significant changes in surface topography and differential electrostatic charge distribution. A comparison of the electrostatic potential surfaces computed from the GI.7 and GI.1 P domain structures shows dramatic charge reversals in the surface-exposed regions of the P2 subdomain, and some of these changes are in close proximity to the HBGA binding site (Fig. 4) . These electrostatic potential surface differences along with surface topography changes likely indicate antigenic variations among GI NoVs.
HBGA binding in GI.7. To examine how the observed structural changes in the GI.7 P domain affect HBGA binding specificities, we crystallized the GI.7 P domain with glycans of ABH secretor, Lewis secretor, and Lewis nonsecretor HBGA families. The HBGAs used were mainly of type 2 precursor backbones, in contrast to the type 1 precursor HBGAs used in the previous structural studies, so as to understand the structural basis of recognition of different HBGA types (1-3) among GI NoVs. Crystals of the P domain-HBGA complexes were obtained by soaking native crystals of the GI.7 P domain (P1 space group with four molecules in the asymmetric unit) with an excess of each carbohydrate ligand. Each of these crystals diffracted to a resolution similar to that of the unliganded P domain crystals. Statistics of data collection and structure refinement for each of the complex structures are given in Table 1 . In each case, the ligand density was clearly visualized (see Fig. S1 in the supplemental material), and unless mentioned otherwise, all the carbohydrate residues in the ligand could be modeled unambiguously into the density map. The bound ligand was validated further using simulated annealing omit maps. H-and A-type HBGA binding to GI.7. We determined the structure of GI.7 in complex with H-type 2 and A-type 2 HBGAs. The HBGA binding site in GI.7, similar to those of other GI strains, is located on the outermost surface-exposed region of the P2 subdomain in close proximity to the variable P-, S-, and Tloops (Fig. 5A) . The H-and A-type HBGA binding predominantly involves direct interactions with residues contributed from individual subunits of the P domain dimer. However, residues from the opposing subunit in the dimer participate in ligand binding through water-mediated interactions (data not shown). Although the H-and A-type binding in GI.7 is generally similar to that observed in GI.1 and GI.2, there are noticeable differences because of the sequence variations that can potentially confer differential affinities for these HBGAs.
The H-type HBGA interacts with the P domain primarily through ␤-Gal and SeFuc; the GlcNAc moiety of the trisaccharide does not participate in direct interactions. ␤-Gal is firmly anchored in the binding site by an extensive network of hydrogen bond interactions involving its exocyclic hydroxyl groups and residues D332, H334, S387, P388, and S391 (Fig. 5B ). A comparison with the H-type HBGA-bound P domain structures of GI.1 (Fig.  5C ) and GI.2 (Fig. 5D) shows that residues D332, H334, and S387 are structurally conserved. These residues are also totally conserved across the GI NoVs as determined by sequence comparison (Fig. 1) . The P388 residue, which structurally corresponds to P378 in GI.1 and Q389 in GI.2, shows significant variation across GI NoVs (Fig. 1) . The S391 residue interaction is unique to GI.7. This residue in the T-loop is positioned in close proximity to ␤-Gal because of the conformational change, allowing it to participate in the hydrogen bond interaction. Analogous interactions in GI.1 and GI.2 are not possible, as the T-loop lies at a distance of 7 Å from ␤-Gal. The GI.7 P domain also exhibits variations from GI.1 and GI.2 with respect to its interactions with the SeFuc of the H-type. In GI.7, the side chain of R351 makes a hydrogen bond with SeFuc. This residue is also involved in hydrogen bond interactions with the D353 residue. Both these residues show significant variations across GI NoVs. In GI.1, each member of the corresponding pair of residues (Q342 and D344) contributes directly to HBGA binding, whereas in GI.2, the corresponding residues (S350 and S352) do not participate in hydrogen bonding to SeFuc due to their shorter side chains. A conserved feature, however, is the hydrophobic interaction involving SeFuc. The hexose ring of the SeFuc moiety makes van der Waals contact with the indole ring of W385, which, in turn, is involved in a cation-pi interaction with H334. Both these interactions are observable in the GI.1 and GI.2 structures, and the two residues are also exceptionally well conserved across GI NoVs.
With respect to A-type tetrasaccharide binding, while three of the four saccharide moieties that showed interactions with the P domain were clearly visible at a contour level of 3 , the density for the terminal GlcNAc was weak and required lowering of the contour level to 2.5 and showed no interactions with the P domain. As observed in the case of H-type binding, sequence variations in the P domain result in several differential interactions along with some conserved features. In GI.7 (Fig. 6A) , as in GI.1 (Fig. 6B ) and GI.2 (Fig. 6C) , binding of the A-type to the P domain is primarily mediated by the N-acetylgalactosamine (GalNAc) moiety. A-type binding shares several similarities with H-type binding. In GI.7, the hexose ring (Gal) of GalNAc shows hydrogen bond interactions with residues D332, H334, S387, P388, and S391 similar to those shown by ␤-Gal in H-type binding, and the N-acetyl arm participates in interactions similar to those of SeFuc of the H-type, including hydrophobic interactions with W385 and hydrogen bonding interactions with R351 (Fig. 6A ). This hydrogen bond interaction involving R351 is not observed in GI.1 and GI.2, as the structurally corresponding residues Q342 in GI.1 and S350 in GI.2, with their shorter side chains, cannot be in close proximity to the N-acetyl arm. However, some of the other GI NoVs have a lysine at this position that could make hydrogen bonds similar to those made by R351 (Fig. 1) . In addition to interactions involving GalNAc, in GI.1, GI.2, and GI.7, SeFuc of the A trisaccharide participates in binding through hydrogen bonding interactions involving a P domain residue. While serine residues in GI.1 (S380) and GI.2 (S391) participate in the hydrogen bonding, in GI.7, due to structural changes, a lysine residue (K355) participates in the hydrogen bonding. These results clearly show that although the GI strains can bind A-and H-type HBGAs, the affinity to these ligands might be modulated in a strain-dependent manner based on the sequence variations and structural changes in the P domain.
P domain-secretor Lewis HBGA binding. To examine how sequence and structural variations in GI.7 affect the binding of difucosyl HBGA, we determined the structure of GI.7 in complex with the Le y (type 2) tetrasaccharide. The structural analysis showed that SeFuc and ␤-Gal of Le y occupy the same positions as described for the H-type above, making nearly identical interactions with the P domain residues (Fig. 7A) . In addition to these interactions involving SeFuc and ␤-Gal, LeFuc of difucosyl Le y participates in a direct hydrogen bonding interaction with the G346= (the prime indicates that the residue is from the opposing subunit) residue located on the P-loop of the opposing subunit in the dimer (Fig. 7A) . Thus, in contrast to A-and H-type HBGA binding, Le y binding involves residues from both subunits of the dimer. The only other structure for comparison with GI.7 in regard to difucosyl binding is that of GI.2 with Le b (Fig. 7B) . With respect to the SeFuc and ␤-Gal moiety interactions, the GI.7 and GI.2 structures exhibit the same differential interactions as described above for H-type binding. With regard to LeFuc, a similar hydrogen bond interaction is observed with G346= in GI.7 as was described for GI.2 involving G345=, despite the shorter P-loop in GI.7. The main difference, however, is that the hydrogen bonding interaction between LeFuc and Q389 observed in GI.2 is absent in GI.7 with a Pro in the corresponding position. Although biochemical studies show that GI.1 can bind to difucosyl HBGAs such as Le y (45) , the structural basis of this interaction has not been determined. In the absence of the structure, we modeled the GI.7-bound Le y onto the GI.1 P domain structure (PDB ID 2ZL6) (Fig. 7C) . The model shows that GI.1 can interact with SeFuc and ␤-Gal similarly to GI.7 or GI.2, with the same differential interactions as noted above for H-type binding. However, the modeling suggests that the analogous hydrogen bond interaction between LeFuc and a Gly residue as observed in GI.2 and GI.7 structures is unlikely because the the P-loop in GI.1 is significantly shorter than the P-loop in either GI.7 or GI.2.
GI.7 P domain binding to nonsecretor Lewis HBGAs. To examine if monofucosyl nonsecretor Lewis HBGAs can bind to the GI.7 P domain in the absence of the Q389 residue and a longer P-loop, which are shown to be critical for nonsecretor HBGA binding in the case of GI.2 (25), we determined the structure of the GI.7 P domain in complex with both Le x (type 2) and Le a (type 1). These nonsecretor HBGAs are monofucosyl with only LeFuc linked to GlcNAc of the precursor disaccharide. Despite the absence of the Q389 and a longer P-loop, our results show that the GI.7 P domain can bind to both Le x and Le a nonsecretor HBGAs. In the Le x -bound GI.7 P domain structure (Fig. 8A) , both the ␤-Gal and LeFuc moieties are involved in hydrogen bonding interactions with the P domain residues. The interactions involving the hexose ring of the ␤-Gal are essentially similar to those observed with the other HBGA interactions described above, and the hydrogen bond interactions involving LeFuc and G346= are also the same as those observed with LeFuc of the difucosyl Lewis HBGA. The differential interactions because of the sequence and structure variations in GI.7 in comparison with GI.2 also remain the same (Fig. 8B) . Modeling of Le x onto GI.1 (data not shown) suggests that while GI.1 can bind the ␤-Gal moiety, the interactions with LeFuc are unlikely to be due to the shorter P-loop in GI.1.
In the P domain structure bound to nonsecretor Le a (type 1) (Fig. 8C) , Le a binds in a manner similar to that for Le x . The ␤-Gal and LeFuc moieties of Le a occupy identical positions and participate in hydrogen bonding interactions similar to those of Le x . The difference between the two structures is with respect to the orientation of the GlcNAc moiety that flips 180°between the two structures. The flip is due to the different glycosidic linkage in the precursor disaccharide. It is noteworthy, however, that in the GI.7-Le a complex structure, although the density for GlcNAc, LeFuc, and ␤-Gal are clearly represented at a contour level of ϳ3 in one of the molecules, in the other 3 molecules of the asymmetric unit, the densities are weaker and required lowering of the contour levels to 2.5 to model the HBGAs.
DISCUSSION
Human NoVs are suggested to evolve based on changing glycan binding specificities and antigenic drift, resulting from the accumulation of sequence variations on the outermost surface-exposed P domain of VP1. This has been particularly well studied in the GII NoVs, with the most prevalent genotype, GII.4, shown to undergo epochal evolution (30, 46, 47) . Such studies are limited for the GI NoVs, in which it remains poorly understood how sequence variations that affect the P domain structure can lead to altered glycan binding specificities and possible antigenic variation. In this study, we determined the P domain structure from a member of the GI.7 genotype that bound to secretor and nonsecretor HBGAs. By comparing the GI.7 structure to the available GI.1 and GI.2 P domain structures, we were able to characterize how sequence variations affect the P domain structure and differentially alter the glycan binding and to identify strain-dependent structural determinants of HBGA binding among the GI NoVs.
Sequence variations results in significant structural changes in the P domain of GI NoVs. A striking observation from our structural studies is that although the overall P domain structure is conserved among the GI NoVs, sequence variations profoundly alter the outermost loop regions (Fig. 3) . These changes also sig- GI.7 P domain (cyan and blue) and Le y (A), GI.2 P domain (orange and olive) and Le b (PDB ID 3ASS) (B), and GI.1 P domain (light gray and dark gray) and modeled Le y (C). In the interactions with secretor Lewis HBGA, SeFuc and ␤-Gal bind in a way similar to that of the H-type, and similar to the case with H-type binding, all hydrogen bond interactions with these two moieties are maintained in both GI.7 and GI.2. Additionally, LeFuc is involved in hydrogen bonding to a Gly residue (G346 for GI.7 and G345 for GI.2) from the other monomer. The modeling of Le y onto the GI.1 P domain shows that Le y can interact with SeFuc and ␤-Gal in a way similar to that of the H-type, and similar to the case with the H-type, all hydrogen bonding interactions are possible (data not shown). A cartoon representation of the secretor Lewis tetrasaccharide is shown at the top right corner.
nificantly affect the surface topography of the P2 subdomain, accompanied by several electrostatic charge reversals (Fig. 4) . One major difference is in the A-and B-loops, which lie in close proximity to each other. In the GI.7 P domain structure, these two loops are well separated in a distinctly open conformation, exposing a large surface area underneath, in contrast to the closed conformation found in the GI.1 and GI.2 strains. Sequence alignment suggests that the A-and B-loops are likely even longer in the GI.8 and GI.9 strains (Fig. 1) . Interestingly, in GI.1 NV, the B loop contains a residue critical for binding of HBGA blocking antibodies (48) , and the corresponding loops in the P domains of murine NoV (GV) (49, 50) and rabbit hemorrhagic disease virus (animal calicivirus) (51) contain the neutralization antigenic sites. Thus, this region can be a major site for potential differential antigenic presentations contributing to serotypic differentiation among the GI variants, a factor that may have to be considered in designing antiviral strategies for GI NoVs.
The P-and S-loops also show significant structural changes among the structurally characterized GI P domains and are seen to deviate in a concerted manner (Fig. 3D ). Although these loops are distant within each subunit in the dimer, they come closer to each other in the context of the dimer and lie in the close vicinity of the HBGA binding site. Sequence comparison among the representative GI variants shows that these loops vary in both length and composition among the representative GI strains. Our studies also revealed another loop region (T-loop) that is susceptible to significant structural changes (Fig. 3F) . In contrast to the GI.1 and GI.2 P domains, the sequence variations in the GI.7 P domain bring the T-loop closer to the HBGA binding site. A sequence comparison of the T-loops among different GI strains shows that the T-loop is shorter in most GI strains, including GI.6, GI.8, and GI.9 strains (Fig. 1) . These structural changes as a result of sequence variations among the GI variants thus could allow GI NoVs to fine-tune and modulate both antigenicity and glycan binding affinities and contribute to the evolution of GI NoVs. Similar alterations in surface topology and electrostatic charge reversals along with variations in HBGA binding specificities are also observed among the more prevalent GII.4 genotype and have been linked to epochal evolution in these variants (30) .
Sequence variations in the GI P domain can potentially modulate HBGA binding affinities. Our studies on GI.7 with monofucosyl and difucosyl secretor HBGAs substantiate the previous observation that HBGA binding in GI NoV involves primarily a Gal moiety, in contrast to the Fuc moiety in GII NoVs, and a highly conserved hydrophobic interaction. Despite the significant sequence variations and consequent structural changes, the residues involved in Gal binding (D332, H334, and S387) and hydrophobic interactions (W385) are positioned in nearly identical positions in the structurally conserved ␤-strands in all GI P domain structures. These residues are also exceptionally well conserved in all the GI NoVs, suggesting that they all should exhibit binding to similar sets of HBGAs. However, comparative analysis of GI P domain structures with HBGAs indicate that the relative affinities of HBGA binding are likely to be differentially modulated by the other residues in the loop regions that show significant structural changes because of associated sequence variations. This is clearly evident in GI.7, in which, for example, the structural changes in the T-loop allows residue S391 to hydrogen bond to the Gal moiety, whereas an analogous interaction is absent in the case of GI.1 and GI.2. Another example is in the GI.1 structure, in which Q342 and D344 contribute to hydrogen bonding to the SeFuc moiety. In the GI.7 P domain structure, Q342 is replaced by R351, which contributes to hydrogen bonding to SeFuc, and D353, which is in the position of GI.1 D344, hydrogen bonds with R351 instead of with SeFuc. In GI.2, these residues are replaced by S350 and S352 and do not interact with SeFuc (Fig. 5) . In the binding of the difucosyl Lewis HBGAs also, in addition to the above-mentioned differences in Gal binding, the GI.7 and GI.2 structures show differential interactions with LeFuc. Although the contributions of such differential interactions to relative HBGA binding affinities may be subtle in the context of the P domain, in the context of the virion during infection, the differences in binding affinities may be more pronounced and discriminatory considering the added avidity effects.
How and whether such differential affinities in HBGA binding contribute to relative differences in productive infection and/or prevalence between GI strains (also true for GII strains) is an interesting question. While the interplay between antigenic varia-tion and HBGA binding specificity is one major factor, productive infection and/or prevalence may be dependent upon a certain threshold affinity for a particular HBGA or set of HBGAs and their abundance in the gut during infection. Experimental verification of such a hypothesis requires an infectivity model for human NoVs, which is not currently available.
The P-loop structure is the determinant in strain-dependent binding of nonsecretor Lewis HBGAs. While many studies have clearly indicated that the majority of the GI NoVs bind to secretor Lewis HBGAs, only a subset of GI NoVs bind nonsecretor Lewis HBGAs. As a structural basis for why only a subset of GI NoVs bind to nonsecretor Lewis HBGAs, based on the studies with GI.2 NoV, it was suggested that Q389 and a longer P-loop are critical determinants for binding (25) . Our in vitro binding studies using GI.7 VLPs and our crystallographic studies clearly showed that despite a Pro residue (P388) in the structurally equivalent position of Q389, the GI.7 P domain can indeed bind nonsecretor Lewis HBGA (Fig. 8) . Despite a shorter P-loop in GI.7 than that in the GI.2, the main-chain amide group of G346= is in place to hydrogen bond with LeFuc as in GI.2. Thus, it is very likely that the threshold length and the structure of the P-loop, which allow main-chain interaction with LeFuc of this HBGA, are the sole critical determinants in nonsecretor HBGA binding. In G1.1 NV, the P loop is significantly shorter and cannot make analogous interactions with LeFuc of the nonsecretor HBGAs. In the GI.3 NoV, recent epidemiological studies have shown a secretor-independent infection pattern (11) . Although this strain has a Pro residue corresponding to Q389 in GI.2 residues, the P-loop length is predicted to be the same as in GI.7 on the basis of the sequence, further supporting the idea that the threshold length of P-loop is critical. From these observations, it can be predicted that genotypes such as GI.4, GI.8, and GI.9 would have the appropriate P-loop length to bind nonsecretor HBGAs, and indeed, Shirato et al. (22) have demonstrated binding of GI.4 and GI.8 VLPs to Le a . HBGA precursor types have minimal structural effects on binding. Our studies also provide valuable structural insight into whether the type of glycoside linkage in the precursors has any effect on HBGA binding to GI NoVs. Most of our studies on GI.7 were done with HBGAs with a type 2 disaccharide precursor (␤-Gal1-4GlcNac) and, in the case of Le a , with a type 1 precursor (␤-Gal1-3GlcNAc), whereas previous studies on GI.1 and GI.2 have used HBGAs with a type 1 disaccharide precursor. Our studies in comparison with GI.1 and GI.2 show that all the hydrogen bond and hydrophobic interactions remain invariant and are not affected by the glycosidic linkage of the precursor. GlcNAc does not make any direct contact with the P domain in any of the structures. The linkage affects the orientation of the terminal GlcNAc moiety and flips this moiety 180°to reverse the direction of its N-acetyl arm. Our structural studies of GI.7 with A-type 3 HBGA (␤-Gal1-3GalNac) also showed (data not shown) the same interactions as with the A-type 2 HBGA, further confirming that the type of precursor has minimal effects on the P domain-HBGA interactions. However, previous studies have indicated qualitative differences between HBGAs with different precursor types (22) . Although no changes have been observed structurally, the reversal of the N-acetyl arm could lead to an additional solvent-mediated hydrogen bond(s) with one type and not the other to bring about small affinity changes, which may be accentuated in the context of VLPs due to avidity effects.
Conclusion. Recent epidemiological studies have shown increased prevalence of GI NoVs. Although secretor-positive status is strongly correlated with NoV infection, cases of NoV infection associated with secretor-negative individuals are reported. Biochemical studies have shown that GI NoVs exhibit genotype-dependent binding to nonsecretor HBGAs. Our main focus was to understand how genotypic differences in GI NoVs affect the P domain structure and HBGA binding specificities. Our studies of GI.7 in comparison with similar studies on GI.2 and GI.1 demonstrate how genotypic differences translate to extensive structural changes in the loop regions that significantly alter the surface topography, perhaps reflective of antigenic variations, and also differentially alter the HBGA binding characteristics. We have identified two loops in the P2 subdomain that exhibit large conformational changes and suggested that they represent major sites for differential antigenic presentations contributing to serotype differentiation. A significant finding from our studies is that the threshold length and the structure of the P loop are critical determinants in the binding of GI NoVs to nonsecretor HBGAs. Further epidemiological studies are required to assess the contribution of such genotype-dependent binding to nonsecretor HBGAs in GI NoVs during NoV infection.
